Document:

Exhibit
10.6

 

SELECTIS
HEALTH, INC. 

 

Whistleblower
Policy

 

Procedures
for the Submission of Complaints or Concerns regarding Financial Statement or other Disclosures, Accounting, Internal Accounting or Disclosure
Controls, Auditing Matters or violations of the Selectis Health, Inc. Code of Business Conduct and Ethics.

 

Section
301 of the Sarbanes-Oxley Act requires the Audit Committee of the Board of Directors of Selectis Health, Inc. (the “Company”)
to establish procedures for: (a) the receipt, retention, and treatment of complaints received by the Company regarding accounting, internal
accounting controls, or auditing matters; and (b) the submission by employees of the Company and others, on a confidential and anonymous
basis, of good faith concerns regarding questionable accounting or auditing matters.

 

In
accordance with Section 301, the Audit Committee has adopted the following procedures:

 

1. The
Company shall promptly forward to the Audit Committee any complaints that it has received regarding financial statement disclosures,
accounting, internal accounting or disclosure controls or auditing matters, disclosure violations or violations of its Code of Business
Conduct and Ethics.

 

2. Any
employee of the Company may submit, on a confidential, anonymous basis if the employee so desires, any good faith concerns regarding
financial statement or other disclosure, accounting, internal accounting or disclosure controls, auditing matters or violations of the
Company’s Code of Business Conduct and Ethics. All such concerns shall be set forth in writing and forwarded in a sealed envelope
to the Chairman of the Audit Committee in an envelope labeled with a legend such as: “To be opened by the Audit Committee only.
Being submitted pursuant to the “whistleblower policy” adopted by the Audit Committee.” If an employee would like
to discuss any matter with the Audit Committee, the employee should indicate this in the submission and include a telephone number at
which he or she might be contacted if the Audit Committee deems it appropriate.

 

3. Following
the receipt of any complaint submitted hereunder, the Audit Committee will investigate each such matter so reported and take corrective
and disciplinary actions, if appropriate, which may include, alone or in combination, a warning or letter of reprimand, demotion, loss
of merit increase, loss of bonus or stock options, suspension without pay or termination of employment.

 

4. The
Audit Committee may enlist committee members, Board members, employees of the Company and/or outside legal, accounting or other advisors,
as appropriate, to conduct any investigation of complaints regarding financial statement disclosures, disclosure concerns or violations,
accounting, internal accounting controls, auditing matters or violations of the Company’s Code of Business Conduct and Ethics.
In conducting any investigation, the Audit Committee shall use reasonable efforts to protect the confidentiality and anonymity of the
complainant.

 

    	1

     

    

 

5. The
Company does not permit retaliation of any kind against employees for complaints submitted hereunder that are made in good faith. Additionally,
no employee shall be adversely affected because the employee refuses to carry out a directive which, in fact, constitutes corporate fraud,
or is a violation of state or federal law or of the Company’s Code of Business Conduct and Ethics.

 

6. The
Audit Committee shall retain as a part of the records of the Audit Committee any such complaints or concerns for a period of no less
than seven (7) years.

 

7. Problems
or concerns related to financial statement or other disclosures, accounting, internal or disclosure controls, auditing matters or questions,
disclosure violations or violations of the Company’s Code of Business Conduct and Ethics, which an employee wishes to discuss or
report on a non-confidential or non-anonymous basis, should be reported immediately to the Company’s Lead Director using the contact
information specified below, or if the employee is uncomfortable reporting to such person, to the Company’s outside legal counsel
using the contact information specified below.

 

8. The
Lead Director or outside counsel, as the case may be, shall keep a written record of all such reports or inquiries and make monthly reports
of the same to the Chairman of the Audit Committee in any month in which an inquiry or complaint is received. If the contact is in the
nature of an alleged violation of the Company’s Code of Conduct and Ethics or an impropriety with regard to the Company’s
financial statements or other disclosures, accounting, internal or disclosure controls, or auditing matters, the allegation shall immediately
be relayed by the Lead Director, or the Company’s outside legal counsel, to the Chairman of the Audit Committee, who shall immediately
notify the complainant that the complaint has been received and begin the procedures outlined above.

 

	Contact
    Information	 	 
	 	 	 
	Audit
    Committee Chairman	 	David
    Furstenberg
	 	 	dfurstenberg@comcast.net
	 	 	 
	Outside
    Legal Counsel	 	Clifford
    L. Neuman, P.C.
	 	 	clneuman@neuman.com

 

    	2Exhibit 10.1

 

SECURITIES PURCHASE AGREEMENT

 

This Securities Purchase Agreement
(this “Agreement”) is dated as of July 28, 2022, between Synthetic Biologics, Inc., a Nevada corporation (the “Company”),
and MSD Credit Opportunity Master Fund, L.P. ( including its successors and assigns, the “Purchaser”).

 

RECITALS

 

A. The Company and the Purchaser
are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of
the Securities Act of 1933, as amended (the “Securities Act”), and/or Rule 506 of Regulation D as promulgated by the
United States Securities and Exchange Commission (the “SEC”) under the Securities Act; and

 

B. The Purchaser wishes to
purchase from the Company, and the Company wishes to sell and issue to the Purchaser, upon the terms and subject to the conditions stated
in this Agreement, shares of the Company’s preferred stock, par value $0.001 per share (the “Preferred Stock”),
that are convertible into shares of the Company’s common stock, $0.001 par value per share (the “Common Stock”).

 

In consideration of the mutual
promises made herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
parties hereto agree as follows:

 

ARTICLE I.

DEFINITIONS

 

1.1 Definitions. In
addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings set
forth in this Section 1.1:

 

“Acquiring Person”
shall have the meaning ascribed to such term in Section 4.4.

 

“Action”
shall have the meaning ascribed to such term in Section 3.1(j).

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act. 

 

“Anti-Money Laundering
Laws” shall have the meaning ascribed to such term in Section 3.1(kk).

 

“Authorized Common
Stock Increase” means the amendment to the Company’s articles of incorporation to, after the date hereof, increase the
number of authorized shares of Common Stock from 20,000,000 to 350,000,000.

 

“Authorized Common
Stock Increase Amendment” means the amendment to the Company’s certificate of incorporation that effects the Authorized
Common Stock Increase.

 

“Authorized Common
Stock Increase Date” means the earlier of (i) the date on which the Authorized Common Stock Increase Amendment becomes effective
under the NRS and (ii) October 26, 2022 or, solely to the extent required for the Company to solicit proxies from its stockholders for
the purposes of obtaining the Stockholder Approvals, December 31, 2022. 

 

“Board of Directors”
means the board of directors of the Company.

 

     

     

    

 

“Business Day”
means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking
institutions in the State of New York are authorized or required by law or other governmental action to close.

 

“Closing”
means the closing of the purchase and sale of the Shares pursuant to Section 2.1.

 

“Closing Date”
means the first Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto,
and all conditions precedent to (i) the Purchaser’s obligations to pay the Subscription Amount and (ii) the Company’s obligations
to deliver the Shares, in each case, have been satisfied or waived, but in no event later than the second (2nd) Trading Day following
the date hereof.

 

“Commission”
means the United States Securities and Exchange Commission.

 

“Common Stock”
means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities may hereafter
be reclassified or changed.

 

“Company Stock Plans
shall have the meaning ascribed to such term in Section 3.1(g).

 

“Disclosure Schedules”
means the disclosure schedules of the Company delivered concurrently herewith.

 

“Conversion Shares”
means shares of Common Stock issuable upon conversion of the Shares.

 

“Disclosure Window”
means between 4:01 p.m. and 5:30 p.m. (New York City time) on the date of this Agreement.

 

“Effective Date”
shall have the meaning ascribed to such term in Section 4.1(b).

 

“Environmental Laws”
shall have the meaning ascribed to such term in Section 3.1(m).

 

“Evaluation Date”
shall have the meaning ascribed to such term in Section 3.1(s).

 

“Exchange Act”
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“FCPA”
means the Foreign Corrupt Practices Act of 1977, as amended.

 

“FDA” shall
have the meaning ascribed to such term in Section 3.1(hh).

 

“FDCA”
shall have the meaning ascribed to such term in Section 3.1(hh).

 

“Financial Advisor”
means A.G.P./Alliance Global Partners.

 

“GAAP”
shall have the meaning ascribed to such term in Section 3.1(h).

 

“Hazardous Materials”
shall have the meaning ascribed to such term in Section 3.1(m).

 

“Indebtedness”
shall have the meaning ascribed to such term in Section 3.1(mm). 

 

    	 	2	 

     

    

 

“Intellectual Property
Rights” shall have the meaning ascribed to such term in Section 3.1(p).

 

“Issuer Covered Person”
means the Company, any of its predecessors, any affiliated issuer, nor, to its knowledge, any director, executive officer, other officer
of the Company participating in the offering hereunder, any beneficial owner of 20% or more of the Company’s outstanding voting
equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities
Act) connected with the Company in any capacity at the time of sale.

 

“IT Systems and Data”
shall have the meaning assigned to such term in Section 3.1(oo).

 

“Liens”
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.

 

“Material Adverse
Effect” shall have the meaning assigned to such term in Section 3.1(b).

 

“Material Permits”
shall have the meaning ascribed to such term in Section 3.1(n).

 

“Name Change”
means the amendment to the Company’s articles of incorporation to, after the date hereof, change the name of the Company to “Theriva
Biologics, Inc.”

 

“NRS” means
the Nevada Revised Statutes.

 

“Options”
shall have the meaning ascribed to such term in Section 3.1(g).

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Pharmaceutical Product”
shall have the meaning ascribed to such term in Section 3.1(hh).

 

“Preferred Stock”
means the Series C Preferred Stock and Series D Preferred Stock of the Company, each with a par value $0.001 per share.

 

“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition) pending or, to the Company’s knowledge, threatened in writing against or affecting the Company, any Subsidiary
or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority
(federal, state, county, local or foreign).

 

“Purchaser Party”
shall have the meaning ascribed to such term in Section 4.7.

  

“Required Approvals”
shall have the meaning ascribed to such term in Section 3.1(e).

 

“Rule 144”
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.

 

“SEC Reports”
shall have the meaning ascribed to such term in Section 3.1(h).

 

“Securities Act”
means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

    	 	3	 

     

    

 

“Series C Certificate
of Designation” means the certificate of designation for the Series C Preferred Stock to be filed with the State of Nevada.

 

“Series C Preferred
Stock” means the Company’s Series C Convertible Preferred Stock issued hereunder having the rights, preferences and privileges
set forth in the Series C Certificate of Designation.

 

“Series D Certificate
of Designation” means the certificate of designation for the Series D Preferred Stock to be filed with the State of Nevada.

 

“Series D Preferred
Stock” means the Company’s Series D Convertible Preferred Stock issued hereunder having the rights, preferences and privileges
set forth in the Series D Certificate of Designation.

 

“Shares”
means the shares of Preferred Stock issued or issuable to Purchaser pursuant to this Agreement.

 

“Short Sales”
means all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include
locating and/or borrowing shares of Common Stock).

 

“Stated Value”
means $8.00 per share of Preferred Stock.

 

“Stockholder Approvals”
means the Company’s stockholders approval of the Authorized Common Stock Increase, Name Change and any proposal to adjourn any meeting
of stockholders called for the purpose of voting on the Authorized Common Stock Increase, pursuant to the Nevada Revised Statutes.

 

“Subscription Amount”
means, as to Purchaser, the aggregate dollar amount of Shares purchased hereunder as specified below Purchaser’s name on the signature
page of this Agreement and next to the heading “Subscription Amount,” in United States dollars and in immediately available
funds.

 

“Subsidiary”
means any subsidiary of the Company as set forth on Schedule 3.1(a), and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.

 

“Trading Day”
means a day on which the principal Trading Market is open for trading.

 

“Trading Market”
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the
NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange (or any
successors to any of the foregoing).

 

“Transaction Documents”
means this Agreement, the Series C Certificate of Designation, the Series D Certificate of Designation, and all exhibits and schedules
thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.

 

“Transfer Agent”
means Equiniti Trust Company, the current transfer agent of the Company, with a mailing address of 275 Madison Avenue, 34th
Floor, New York, New York 10016, and any successor transfer agent of the Company.

 

    	 	4	 

     

    

 

ARTICLE II.

PURCHASE AND SALE

 

2.1 Closing. On the
Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to issue and sell, and the Purchaser agrees
to purchase, an aggregate of $2,200,000 of Series C Preferred Stock and an aggregate of $800,000 of Series D Stock Preferred Stock with
an aggregate Subscription Amount as set forth on the signature page hereto executed by Purchaser. The aggregate number of shares of Series
C Preferred Stock and Series D Preferred Stock sold hereunder shall be 275,000 and 100,000, respectively. Purchaser shall deliver to the
Company, via wire transfer, a cash amount of immediately available funds equal to its Subscription Amount, and the Company shall deliver
to Purchaser its respective Shares, as determined pursuant to Section 2.2(a), and the Company and Purchaser shall deliver the other
items set forth in Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections
2.2 and 2.3, the Closing shall occur at the offices of the Financial Advisor or such other location as the parties shall mutually
agree.

 

2.2 Deliveries.

 

(a) On or prior to the Closing
Date, the Company shall deliver or cause to be delivered to Purchaser the following:

 

(i) this Agreement duly
executed by the Company;

 

(ii) the Company shall have
provided Purchaser with the Company’s wire instructions, on Company letterhead and executed by the Company’s Chief Executive
Officer and Chief Financial Officer;

  

(iii) a certificate or book
entry evidencing 275,000 shares of Series C Preferred Stock, registered in the name of Purchaser, and evidence of the filing and acceptance
of the Series C Certificate of Designation from the Secretary of State of Nevada;

 

(iv) a certificate or book
entry evidencing 100,000 shares of Series D Preferred Stock, registered in the name of Purchaser, and evidence of the filing and acceptance
of the Series D Certificate of Designation from the Secretary of State of Nevada;

 

(v) a certificate executed
by the Chief Executive Officer and Chief Financial Officer of the Company, dated as of the Closing Date, in form and substance reasonably
acceptable to the Purchaser; and

 

(vi) a certificate executed
by the Secretary of the Company, dated as of the Closing Date, in form and substance reasonably acceptable to the Purchaser.

 

(b) On or prior to the Closing
Date, Purchaser shall deliver or cause to be delivered to the Company the following:

 

(i) this Agreement duly executed
by Purchaser; and

 

(ii) a cash amount equal to
Purchaser’s Subscription Amount by wire transfer to the account specified in writing by the Company. 

 

    	 	5	 

     

    

 

2.3 Closing Conditions.

 

(a) The obligations of the Company
hereunder in connection with the Closing are subject to the following conditions being met:

 

(i) the accuracy in all material
respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) on
the Closing Date of the representations and warranties of the Purchaser contained herein (unless as of a specific date therein in which
case they shall be accurate as of such date);

 

(ii) all obligations, covenants
and agreements of Purchaser required to be performed at or prior to the Closing Date shall have been performed; and

 

(iii) the delivery by Purchaser
of the items set forth in Section 2.2(b) of this Agreement.

 

(b) The obligations of the Purchaser
hereunder in connection with the Closing are subject to the following conditions being met:

 

(i) the accuracy in all material
respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) when
made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of a specific date therein
in which case they shall be accurate as of such date);

 

(ii) all obligations, covenants
and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed in all material respects;

 

(iii) the delivery by the
Company of the items set forth in Section 2.2(a) of this Agreement;

 

(iv) the Company shall have
filed with the Secretary of State of Nevada, and the Secretary of State of Nevada shall have provided evidence of acceptance of, the Series
C Certificate of Designation and the Series D Certificate of Designation;

 

(v) there shall have been
no Material Adverse Effect with respect to the Company since the date hereof; and

 

(vi) from the date hereof
to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company’s principal Trading
Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have been
suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such service, or on
any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities nor shall
there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such magnitude in
its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of Purchaser, makes
it impracticable or inadvisable to purchase the Shares at the Closing.

 

    	 	6	 

     

    

 

ARTICLE III.

REPRESENTATIONS AND WARRANTIES

 

3.1 Representations and
Warranties of the Company. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall be deemed a part hereof
and shall qualify any representation or warranty otherwise made herein to the extent of the disclosure contained in the corresponding
section of the Disclosure Schedules, the Company hereby makes the following representations and warranties to Purchaser:

 

(a) Subsidiaries. All
of the direct and indirect subsidiaries of the Company are set forth on Schedule 3.1(a). The Company owns, directly or indirectly,
all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding
shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights
to subscribe for or purchase securities.

 

(b) Organization and Qualification.
Each of the Company and the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to own and use its properties
and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in violation nor default of
any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational or charter documents.
Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other
entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary,
except where the failure to be so qualified or in good standing, as the case may be, would not have or reasonably be expected to result
in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse effect
on the results of operations, assets, business, or financial condition of the Company and the Subsidiaries, taken as a whole, or (iii)
a material adverse effect on the Company’s ability to perform in any material respect on a timely basis its obligations under any
Transaction Document (any of (i), (ii) or (iii), a “Material Adverse Effect”); provided that a change in the market
price or trading volume of the Common Stock alone shall not be deemed, in and of itself, to constitute a Material Adverse Effect. No Proceeding
has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority
or qualification.

 

(c) Authorization; Enforcement.
The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement
and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery
of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the transactions contemplated
hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the
Company, the Board of Directors or the Company’s stockholders in connection herewith or therewith other than in connection with
the Required Approvals (as defined below). This Agreement and each other Transaction Document to which it is a party has been (or upon
delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute
the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by
general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting
enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive
relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.

 

(d) No Conflicts.
The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it is a party,
the issuance and sale of the Shares and the consummation by it of the transactions contemplated hereby and thereby do not and will
not (i) conflict with or violate any provision of the Company’s or any Subsidiary’s certificate or articles of
incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that
with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or
assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar
adjustments, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt
or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any
Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to
the Required Approvals (as defined below), conflict with or result in a violation of any law, rule, regulation, order, judgment,
injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject
(including federal and state securities laws and regulations), or by which any property or asset of the Company or a Subsidiary is
bound or affected; except in the case of each of clauses (ii) and (iii), such as would not have or reasonably be expected to result
in a Material Adverse Effect.

 

    	 	7	 

     

    

 

(e) Filings, Consents and
Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing
or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the
execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filing of the Series C Certificate
of Designation and Series D Certificate of Designation, (ii) filings pursuant to applicable state and federal securities laws, (iii) the
registration statement required to be filed by this Agreement and (iv) the Stockholder Approvals (collectively, the “Required
Approvals”).

 

(f) Issuance of the Shares.
The Shares have been duly authorized and, subject to the Stockholder Approvals, when issued and paid for in accordance with the applicable
Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company,
except for restrictions on transfer set forth in the Transaction Documents or imposed by applicable securities laws. Subject to the Stockholder
Approvals , the Company has reserved from its duly authorized capital stock the maximum number of shares of Common Stock issuable pursuant
to this Agreement. The Company is eligible to use Form S-3 under the Securities Act.

 

(g) Capitalization.
The Company has an authorized and outstanding capitalization as set forth on Schedule 3.1(g). The Company has not issued any
capital stock since its most recently filed periodic report under the Exchange Act other than pursuant to the exercise of employee
stock options under the Company Stock Plans (as defined below). The shares of Common Stock outstanding prior to the issuance of the
Shares have been duly authorized and are validly issued, fully paid and non-assessable. Except as described in Schedule
3.1(g), there are no options, warrants, agreements, contracts or other rights in existence to purchase or acquire from the
Company or any Subsidiary of the Company any shares of the capital stock of the Company or any Subsidiary of the Company, subject to
the grant of options consistent with past practices. No Person has any right of first refusal, preemptive right, right of
participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. The description of
the Company’s stock option, stock bonus and other stock plans or arrangements (the “Company Stock Plans”),
and the options (the “Options”) or other rights granted thereunder, set forth in the SEC Reports accurately and
fairly presents in all material respects the information required to be shown with respect to such plans, arrangements, options and
rights. Each grant of an Option (A) was duly authorized no later than the date on which the grant of such Option was by its terms to
be effective by all necessary corporate action, including, as applicable, approval by the Board of Directors of the Company (or a
duly constituted and authorized committee thereof) and any required shareholder approval by the necessary number of votes or written
consents, and the award agreement governing such grant (if any) was duly executed and delivered by each party thereto and (B) was
made in accordance with the terms of the applicable Company Stock Plan, and all applicable laws and regulatory rules or
requirements, including all applicable federal securities laws. The issuance and sale of the Shares will not obligate the Company or
any Subsidiary to issue shares of Common Stock or other securities to any Person (other than the Purchaser) and will not result in a
right of any holder of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities.
There are not outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or similar
provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may
become bound to redeem a security of the Company or such Subsidiary. Except as disclosed in Schedule 3.1(g), there are no
stockholder agreements, voting agreements or other similar agreements with respect to the Company’s capital stock to which the
Company is a party or, to the Company’s knowledge, between or among any of the Company’s stockholders.

 

    	 	8	 

     

    

  

(h) SEC Reports; Financial
Statements. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company
under Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the one year preceding the date hereof
(or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including all
exhibits thereto and documents incorporated by reference therein being collectively referred to herein as the “SEC Reports”)
on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration
of such extension. At the time of filing thereof, the SEC Reports complied in all material respects with the requirements of the Securities
Act or the Exchange Act, as applicable, and did not contain any untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary in order to make the statements made therein, in the light of the circumstances under which
they were made, not misleading. The financial statements of the Company included in the SEC Reports complied in all material respects
with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time
of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting principles applied
on a consistent basis during the periods involved (“GAAP”), except as may be otherwise specified in such financial
statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly
present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof
and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial,
year-end audit adjustments.

 

(i) Material Changes;
Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements included within the
SEC Reports (i) there has been no event, occurrence or development that has had or that would reasonably be expected to result in a
Material Adverse Effect, (ii) the Company has not incurred any material liabilities (contingent or otherwise) other than (A) trade
payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities not
required to be reflected in the Company’s financial statements pursuant to GAAP or disclosed in filings made with the
Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or
distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any
shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except
pursuant to existing Company equity compensation or stock option plans. The Company does not have pending before the Commission any
request for confidential treatment of information. Except for the issuance of the Shares contemplated by this Agreement, no event,
liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with
respect to the Company or its Subsidiaries or their respective businesses, prospects, properties, operations, assets or financial
condition that would be required to be disclosed by the Company under applicable securities laws at the time this representation is
made or deemed made that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is
made.

 

    	 	9	 

     

    

 

(j) Litigation. Except
as disclosed in the SEC Reports, there is no material Proceeding, inquiry, notice of violation or investigation pending or, to the Company’s
knowledge, threatened against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator,
governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an “Action”).
None of the Actions set forth in the SEC Reports adversely affects or challenges the legality, validity or enforceability of any of the
Transaction Documents or the Shares or would, if there were an unfavorable decision, have or reasonably be expected to result in a Material
Adverse Effect. Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action
involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has
not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the
Company or any current or former director or officer of the Company. The Commission has not issued any stop order or other order suspending
the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.

 

(k) Labor Relations.
No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company, which would
reasonably be expected to result in a Material Adverse Effect. Except for the employees of VCN Biosciences, S.L., none of the Company’s
or its Subsidiaries’ employees is a member of a union that relates to such employee’s relationship with the Company or such
Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement. To the Company’s
knowledge, no executive officer of the Company or any Subsidiary, is, or is now expected to be, in violation of any material term of any
employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract
or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does
not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its
Subsidiaries are in compliance with all applicable U.S. federal, state, local and foreign laws and regulations relating to employment
and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance would not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

(l) Compliance. Neither
the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived that, with
notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary
received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement or any other
agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation
has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority or (iii)
is or has been in violation of any applicable statute, rule, ordinance or regulation of any governmental authority, including without
limitation all applicable foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and
safety, product quality and safety and employment and labor matters, except in each case as would not have or reasonably be expected to
result in a Material Adverse Effect.

 

(m) Environmental
Laws. The Company and its Subsidiaries (i) are in material compliance with all applicable federal, state, local and foreign laws
relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land
surface or subsurface strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals,
pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials”) into
the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or
handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments,
licenses, notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder
(“Environmental Laws”); (ii) have received all permits licenses or other approvals required of them under
applicable Environmental Laws to conduct their respective businesses; and (iii) are in compliance with all terms and conditions of
any such permit, license or approval where in each clause (i), (ii) and (iii), the failure to so comply would be reasonably expected
to have, individually or in the aggregate, a Material Adverse Effect.

 

    	 	10	 

     

    

 

(n) Regulatory Permits.
The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal, state, local
or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except where the failure
to possess such permits would not reasonably be expected to result in a Material Adverse Effect (“Material Permits”),
and neither the Company nor any Subsidiary has received any notice of any Proceeding relating to the revocation or modification of any
Material Permit.

 

(o) Title to Assets.
The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good and marketable
title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case free and
clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere with the
use made and proposed to be made of such property by the Company and the Subsidiaries, and (ii) Liens for the payment of federal, state
or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which is neither delinquent
nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under
valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance, except where the failure to be
in compliance would not reasonably be expected to have a Material Adverse Effect.

 

(p) Intellectual Property.
The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service
marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights necessary
or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to so have would
have a Material Adverse Effect (collectively, the “Intellectual Property Rights”). None of, and neither the Company
nor any Subsidiary has received a written notice that any of, the Intellectual Property Rights has expired, terminated or been abandoned,
or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement. Neither the Company nor any
Subsidiary has received, since the date of the latest audited financial statements included within the SEC Reports, a written notice of
a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except
as would not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the Company, all such Intellectual
Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights. The
Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their
intellectual properties, except where failure to do so would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect. The Company has no knowledge of any facts that would preclude it from having valid license rights or clear title to the
Intellectual Property Rights. The Company has no knowledge that it lacks or will be unable to obtain any rights or licenses to use all
Intellectual Property Rights that are necessary to conduct its business.

 

(q) Insurance. The
Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in
such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but
not limited to, directors and officers insurance coverage.

 

    	 	11	 

     

    

 

(r) Transactions With Affiliates
and Employees. Except as disclosed in the SEC Reports, none of the officers or directors of the Company or any Subsidiary and, to
the Company’s knowledge, none of the employees of the Company or any Subsidiary is presently a party to any transaction with the
Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement
providing for the furnishing of services to or by, providing for rental of real or personal property to or from, providing for the borrowing
of money from or lending of money to or otherwise requiring payments to or from any officer, director or such employee or, to the Company’s
knowledge, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee,
stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for services
rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock option
agreements under any stock option plan of the Company.

 

(s) Sarbanes-Oxley; Internal
Accounting Controls. The Company and the Subsidiaries are in compliance in all material respects with the applicable requirements
of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated
by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries maintain
a system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance
with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s
general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such
disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits
under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules
and forms. The Company’s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company
and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date,
the “Evaluation Date”). The Company presented in its most recently filed periodic report under the Exchange Act the
conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as
of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such
term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially
affect, the internal control over financial reporting of the Company and its Subsidiaries.

 

(t) Certain Fees. Except
to the Financial Advisor, no brokerage or finder’s fees or commissions are or will be payable by the Company or any Subsidiary to
any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions
contemplated by the Transaction Documents. The Purchaser shall have no obligation with respect to any fees or with respect to any claims
made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions
contemplated by the Transaction Documents.

 

    	 	12	 

     

    

 

(u) Private Placement.
Assuming the accuracy of the Purchaser’s representations and warranties set forth in Section 3.2, no registration under
the Securities Act is required for the offer and sale of the Shares by the Company to the Purchaser as contemplated hereby. The issuance
and sale of the Shares hereunder does not contravene the rules and regulations of the Trading Market.

 

(v) Investment Company.
The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Shares, will not be or be an Affiliate
of, an “investment company” within the meaning of the Investment Company Act of 1940, as amended.

 

(w) Registration Rights.
Except as provided in this Agreement, no Person has any right to cause the Company or any Subsidiary to effect the registration under
the Securities Act of any securities of the Company or any Subsidiary.

 

(x) Listing and Maintenance
Requirements. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no
action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under
the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration. The
Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market on which the Common Stock is or has
been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading
Market. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all
such listing and maintenance requirements. The Common Stock is currently eligible for electronic transfer through the Depository Trust
Company or another established clearing corporation and the Company is current in payment of the fees to the Depository Trust Company
(or such other established clearing corporation) in connection with such electronic transfer.

 

(y) Application of Takeover
Protections. The Company and its Board of Directors have taken all necessary action, if any, in order to render inapplicable any control
share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar anti-takeover
provision under the Company’s articles of incorporation (or similar charter documents) or the laws of its state of incorporation
that is or could become applicable to the Purchaser as a result of the Purchaser and the Company fulfilling their obligations or exercising
their rights under the Transaction Documents, including without limitation as a result of the Company’s issuance of the Shares and
the Purchaser’s ownership of the Shares.

 

(z) Disclosure.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company
confirms that neither it nor, to the Company’s knowledge, any other Person acting on its behalf has provided the Purchaser or
its agents or counsel with any information that it believes constitutes or might constitute material, nonpublic information which is
not otherwise disclosed in the SEC Reports on or prior to the Closing Date. The Company understands and confirms that the Purchaser
will rely on the foregoing representation in effecting transactions in securities of the Company. All of the disclosure furnished by
or on behalf of the Company to the Purchaser regarding the Company and its Subsidiaries, their respective businesses and the
transactions contemplated hereby, including the Disclosure Schedules to this Agreement, is true and correct in all material respects
and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the
statements made therein, in the light of the circumstances under which they were made, not misleading. The press releases
disseminated by the Company during the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the
statements therein, in the light of the circumstances under which they were made and when made, not misleading. The Company
acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions
contemplated hereby other than those specifically set forth in Section 3.2 hereof.

 

    	 	13	 

     

    

 

(aa) No Integrated Offering.
Assuming the accuracy of the Purchaser’s representations and warranties set forth in Section 3.2, neither the Company, nor
any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security
or solicited any offers to buy any security, under circumstances that would cause this offering of the Shares to be integrated with prior
offerings by the Company for purposes of any applicable shareholder approval provisions of any Trading Market on which any of the securities
of the Company are listed or designated.

 

(bb) Tax Status. The
Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income and all foreign income and franchise
tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other governmental
assessments and charges that are material in amount, whether or not shown or determined to be due on such returns, reports and declarations
and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the
periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the
taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.

 

(cc) Foreign Corrupt Practices.
Neither the Company nor any Subsidiary, nor to the Company’s knowledge, any agent or other person acting on behalf of the Company
or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses
related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government officials or employees
or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully any contribution made
by the Company or any Subsidiary (or made by any person acting on its behalf of which the Company is aware) which is in violation of law,
or (iv) violated in any material respect any provision of FCPA.

 

(dd) Accountants. The
Company’s independent registered public accounting firm is set forth in the SEC Reports. To the Company’s knowledge, such
accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) has expressed its opinion with respect
to the financial statements included in the Company’s Annual Report for the fiscal year ended December 31, 2021.

 

(ee) Acknowledgment Regarding
Purchaser’s Purchase of Shares. The Company acknowledges and agrees that each of the Purchaser is acting solely in the capacity
of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby. The Company further
acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect
to the Transaction Documents and the transactions contemplated thereby and any advice given by Purchaser or any of its representatives
or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental to the Purchaser’s
purchase of the Shares. The Company further represents to Purchaser that the Company’s decision to enter into this Agreement and
the other Transaction Documents has been based solely on the independent evaluation of the transactions contemplated hereby by the Company
and its representatives.

 

(ff) Reserved.

 

(gg) Regulation M
Compliance. The Company has not, and to the Company’s knowledge no one acting on its behalf has, (i) taken, directly or
indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the
Company to facilitate the sale or resale of any of the Shares, (ii) sold, bid for, purchased, or paid any compensation for
soliciting purchases of, any of the Shares, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to
purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), compensation paid to the Financial
Advisor in connection with the placement of the Shares.

 

    	 	14	 

     

    

 

(hh) FDA. As to each
product subject to the jurisdiction of the U.S. Food and Drug Administration (“FDA”) under the Federal Food, Drug and
Cosmetic Act, as amended, and the regulations thereunder (“FDCA”) that is manufactured, packaged, labeled, tested and/or
distributed by the Company or any of its Subsidiaries (each such product, a “Pharmaceutical Product”), such Pharmaceutical
Product is being manufactured, packaged, labeled, tested and/or distributed by the Company in compliance with all applicable requirements
under FDCA and similar laws, rules and regulations relating to registration, investigational use, licensure, or application approval,
good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record
keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There is no pending,
completed or, to the Company’s knowledge, threatened, Action (including any arbitration, or legal or administrative or regulatory
Proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its
Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests
the licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the
sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension,
or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product,
(iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any
facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with
the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any
of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business
and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules
and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use
in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern
as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.

 

(ii) Stock Option Plans.
Each stock option granted by the Company under the Company’s stock option plan was granted (i) in accordance with the terms of the
Company’s stock option plan and (ii) with an exercise price at least equal to the fair market value of the Common Stock on the date
such stock option would be considered granted under GAAP and applicable law. No stock option granted under the Company’s stock option
plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company policy or practice to knowingly
grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the release or other public announcement
of material information regarding the Company or its Subsidiaries or their financial results or prospects.

 

(jj) Office of Foreign Assets
Control. Neither the Company nor any Subsidiary nor, to the Company’s knowledge, any director, officer, agent, employee or affiliate
of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the
U.S. Treasury Department.

 

(kk) Anti-Money
Laundering. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with
applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as
amended, applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the
 “Anti-Money Laundering Laws”), and no Action or Proceeding by or before any court or governmental agency,
authority or body or any arbitrator involving the Company or any Subsidiary with respect to the Anti-Money Laundering Laws is
pending or, to the Company’s knowledge, threatened in writing.

 

    	 	15	 

     

    

 

(ll) Other Covered Persons.
Other than the Financial Advisor, the Company is not aware of any person (other than any Issuer Covered Person) that has been or will
be paid (directly or indirectly) remuneration for solicitation of Purchaser in connection with the sale of any Shares.

 

(mm) Solvency. Based
on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company of the
proceeds from the sale of the Shares hereunder, (i) the fair saleable value of the Company’s assets exceeds the amount that will
be required to be paid on or in respect of the Company’s existing debts and other liabilities (including known contingent liabilities)
as they mature, (ii) the Company’s assets do not constitute unreasonably small capital to carry on its business as now conducted
and as proposed to be conducted including its capital needs taking into account the particular capital requirements of the business conducted
by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii) the current cash flow of the
Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated
uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when such amounts are required to be paid.
The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts
of cash to be payable on or in respect of its debt). The Company has no knowledge of any facts or circumstances which lead it to believe
that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from
the Closing Date. Schedule 3.1(mm) sets forth as of the date hereof all outstanding secured and unsecured Indebtedness of the Company
or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement, “Indebtedness”
means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary
course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether or
not the same are or should be reflected in the Company’s consolidated balance sheet (or the notes thereto), except guaranties by
endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (z) the
present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP. Neither
the Company nor any Subsidiary is in default with respect to any Indebtedness.

 

(nn) Regarding
Purchaser’s Trading Activity. Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except for Sections
3.2(f) and 4.11 hereof), it is understood and acknowledged by the Company that: (i) Purchaser has not been asked by the
Company to agree, nor has Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or
 “derivative” securities based on securities issued by the Company or to hold the Shares for any specified term, (ii)
past or future open market or other transactions by Purchaser, specifically including, without limitation, Short Sales or
 “derivative” transactions, before or after the closing of this or future private placement transactions, may negatively
impact the market price of the Company’s publicly-traded securities, (iii) Purchaser, and counter-parties in
 “derivative” transactions to which Purchaser is a party, directly or indirectly, presently may have a
 “short” position in the Common Stock and (iv) Purchaser shall not be deemed to have any affiliation with or control over
any arm’s length counter-party in any “derivative” transaction. The Company further understands and acknowledges
that (y) Purchaser may engage in hedging activities at various times during the period that the Shares are outstanding, and (z) such
hedging activities (if any) could reduce the value of the existing stockholders’ equity interests in the Company at and after
the time that the hedging activities are being conducted. The Company acknowledges that such aforementioned hedging activities do
not constitute a breach of any of the Transaction Documents.

 

    	 	16	 

     

    

 

(oo) Cybersecurity. (i)
There has been no security breach or other compromise of or relating to any of the Company’s or any Subsidiary’s information
technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees, suppliers,
vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively, “IT Systems and Data”)
and (y) the Company and the Subsidiaries have not been notified of, and has no knowledge of any event or condition that would reasonably
be expected to result in, any security breach or other compromise to its IT Systems and Data; (ii) the Company and the Subsidiaries are
presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator
or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems
and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as
would not, individually or in the aggregate, have a Material Adverse Effect; (iii) the Company and the Subsidiaries have implemented and
maintained commercially reasonable safeguards to maintain and protect its material confidential information and the integrity, continuous
operation, redundancy and security of all IT Systems and Data; and (iv) the Company and the Subsidiaries have implemented backup and disaster
recovery technology consistent with industry standards and practices.

 

(pp) Subsidiary Rights.
The Company has the unrestricted right to vote, and (subject to limitations imposed by applicable law) to receive dividends and distributions
on, all capital securities of its Subsidiaries as owned by the Company or any Subsidiary of the Company.

 

(qq) Promotional Stock Activities.
Neither the Company nor any Subsidiary of the Company and none of their respective officers, directors, managers, affiliates or agents
have engaged in any stock promotional activity that could give rise to a complaint, inquiry, or trading suspension by the SEC alleging
(i) a violation of the anti-fraud provisions of the federal securities laws, (ii) violations of the anti-touting provisions, (iii) improper
 “gun-jumping; or (iv) promotion without proper disclosure of compensation. 

 

3.2 Representations and
Warranties of the Purchaser. Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the date hereof
and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate as of
such date):

 

(a) Organization; Authority.
Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing under the laws of the
jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company or similar power and
authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its obligations
hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by Purchaser of the transactions contemplated
by the Transaction Documents have been duly authorized by all necessary corporate, partnership, limited liability company or similar action,
as applicable, on the part of Purchaser. Each Transaction Document to which it is a party has been duly executed by Purchaser, and when
delivered by Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of Purchaser, enforceable
against it in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited
by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.

 

    	 	17	 

     

    

 

(b) Understandings or Arrangements.
Purchaser is acquiring the Shares as principal for its own account and has no direct or indirect arrangement or understandings with any
other persons to distribute or regarding the distribution of such Shares (this representation and warranty not limiting Purchaser’s
right to sell the Shares or otherwise in compliance with applicable federal and state securities laws). Purchaser is acquiring the Shares
hereunder in the ordinary course of its business. Purchaser is acquiring such Shares as principal for his, her or its own account and
not with a view to or for distributing or reselling such Shares or any part thereof in violation of the Securities Act or any applicable
state securities law, has no present intention of distributing any of such Shares in violation of the Securities Act or any applicable
state securities law and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the
distribution of such Shares in violation of the Securities Act or any applicable state securities law (this representation and warranty
not limiting Purchaser’s right to sell such Shares pursuant to a registration statement or otherwise in compliance with applicable
federal and state securities laws).

 

(c) Purchaser Status.
At the time Purchaser was offered the Shares, it was, and as of the date hereof it is, either: (i) an “accredited investor”
as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act or (ii) a “qualified institutional buyer”
as defined in Rule 144A(a) under the Securities Act.

 

(d) Experience of Purchaser.
Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial
matters so as to be capable of evaluating the merits and risks of the prospective investment in the Shares, and has so evaluated the merits
and risks of such investment. Purchaser is able to bear the economic risk of an investment in the Shares and, at the present time, is
able to afford a complete loss of such investment.

 

(e) Access to Information.
Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits and schedules thereto)
and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers
from, representatives of the Company concerning the terms and conditions of the offering of the Shares and the merits and risks of investing
in the Shares; (ii) access to information about the Company and its financial condition, results of operations, business, properties,
management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional information
that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision
with respect to the investment. Purchaser acknowledges and agrees that neither the Financial Advisor nor any Affiliate of the Financial
Advisor has provided Purchaser with any information or advice with respect to the Shares nor is such information or advice necessary or
desired. Neither the Financial Advisor nor any Affiliate has made or makes any representation as to the Company or the quality of the
Shares and the Financial Advisor and any Affiliate may have acquired non-public information with respect to the Company which Purchaser
agrees need not be provided to it. In connection with the issuance of the Shares to Purchaser, neither the Financial Advisor nor any of
its Affiliates has acted as a financial advisor or fiduciary to Purchaser.

 

(f) Certain
Transactions and Confidentiality. Other than consummating the transactions contemplated hereunder, Purchaser has not, nor has
any Person acting on behalf of or pursuant to any understanding with Purchaser, directly or indirectly executed any purchases or
sales, including Short Sales, of the securities of the Company during the period commencing as of the time that Purchaser first
received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material
terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the
foregoing, in the event Purchaser is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions
of Purchaser’s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio
managers managing other portions of Purchaser’s assets, the representation set forth above shall only apply with respect to
the portion of assets managed by the portfolio manager that made the investment decision to purchase the Shares covered by this
Agreement. Other than to other Persons party to this Agreement or to Purchaser’s representatives, including, without
limitation, its officers, directors, partners, legal and other advisors, employees, agents and Affiliates, Purchaser has maintained
the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this
transaction). Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation
or warranty against, or a prohibition of, any actions with respect to the borrowing of, arrangement to borrow, identification of the
availability of, and/or securing of, securities of the Company in order for Purchaser (or its broker or other financial
representative) to effect Short Sales or similar transactions in the future.

 

    	 	18	 

     

    

 

(g) General Solicitation.
Purchaser is not purchasing the Shares as a result of any advertisement, article, notice or other communication regarding the Shares published
in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or, to the knowledge of
Purchaser, any other general solicitation or general advertisement.

 

(h) No Government Recommendation
or Approval. Purchaser understands that no United States federal or state agency, or similar agency of any other country, has reviewed,
approved, passed upon, or made any recommendation or endorsement of the Company or the purchase of the Shares.

 

(i) No Intent to Effect a
Change of Control; Ownership. Purchaser has no present intent to effect a “change of control” of the Company as such term
is understood under the rules promulgated pursuant to Section 13(d) of the Exchange Act.

 

(j) No Rule 506 Disqualifying
Activities. Purchaser has not taken any of the actions set forth in, and is not subject to, the disqualification provisions of Rule
506(d)(1) of the Securities Act.

 

(k) Reserved.

 

(l) Restricted Securities.
Purchaser understands that the Shares are characterized as “restricted securities” under the U.S. federal securities laws
inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable
regulations such securities may be resold without registration under the Securities Act only in certain limited circumstances.

 

(m) Legends. It is understood
that, except as provided below, certificates or book entry accounts evidencing the Shares may bear the following or any similar legend:

 

“THE SECURITIES
REPRESENTED HEREBY HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN
RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND, ACCORDINGLY, MAY NOT BE TRANSFERRED
UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, (II) SUCH SECURITIES
MAY BE SOLD PURSUANT TO RULE 144, OR (III) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH
TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NOTWITHSTANDING THE FOREGOING, THE
SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE
SECURITIES.”

 

    	 	19	 

     

    

 

If required by the authorities
of any state in connection with the issuance of sale of the Shares, the legend required by such state authority.

 

The Company acknowledges and
agrees that the representations contained in this Section 3.2 shall not modify, amend or affect Purchaser’s right to rely
on the Company’s representations and warranties contained in this Agreement or any representations and warranties contained in any
other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation
of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute
a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or
similar transactions in the future.

 

ARTICLE IV.

OTHER AGREEMENTS OF THE PARTIES

 

4.1 Transfer Restrictions.

 

(a) The Shares and Conversion
Shares may only be disposed of in compliance with state and federal securities laws. In connection with any sale, assignment, transfer
or other disposition of the Shares or Conversion Shares by a Purchaser pursuant to Rule 144 or pursuant to any other exemption under the
Securities Act, upon compliance by the Purchaser with the requirements of this Agreement and applicable laws, if requested by the Purchaser,
the Company shall cause the Transfer Agent to timely remove any restrictive legends related to the book entry account holding such Shares
and make a new, unlegended entry for such book entry Shares or Conversion Shares sold or disposed of without restrictive legends within
two Business Days of the request of the Purchaser, provided that the Company has received from the Purchaser customary representations,
opinions of legal counsel and other documentation reasonably acceptable to the Company in connection therewith.

 

(b) Subject to receipt from
the Purchaser by the Company and the Transfer Agent of customary representations and other customary documentation reasonably acceptable
to the Company and the Transfer Agent in connection therewith, upon the earliest of such time as (i) the Shares or Conversion Shares have
been sold pursuant to an effective registration statement covering the resale of the Shares or Conversion Shares, or (ii) the Shares or
Conversion Shares have been sold pursuant to Rule 144 (such earliest date, the “Effective Date”), the Company shall
(A) deliver to the Transfer Agent irrevocable instructions that the Transfer Agent shall make a new, unlegended entry for such book entry
Shares, and (B) cause its counsel to deliver to the Transfer Agent, no later than two Trading Days after the Effective Date, one or more
opinions to the effect that the removal of such legends in such circumstances may be effected under the Securities Act if required by
the Transfer Agent to effect the removal of the legend in accordance with such irrevocable instructions and the other applicable provisions
of this Agreement. The Company agrees that following such time as such legend is no longer required under this Section, it will, no later
than two Trading Days following the delivery by a Purchaser to the Company or the Transfer Agent of a certificate representing Shares
or Conversion Shares issued with a restrictive legend, deliver or cause to be delivered to Purchaser a certificate representing such shares
that is free from all restrictive and other legends. The Company may not make any notation on its records or give instructions to the
Transfer Agent that enlarge the restrictions on transfer set forth in this Section.

 

    	 	20	 

     

    

 

(c) Purchaser agrees with the
Company (i) that Purchaser will sell any Shares or Common Stock issuable upon conversion of the Shares pursuant to either the registration
requirements of the Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom, (ii) that if
Shares or Common Stock issuable upon conversion of the Shares are sold pursuant to a registration statement, they will be sold in compliance
with the plan of distribution set forth therein and (iii) that if, after the Effective Date of the registration statement covering the
resale of the Shares, such registration statement is not then effective and the Company has provided notice to Purchaser to that effect,
Purchaser will sell shares only in compliance with an exemption from the registration requirements of the Securities Act. Purchaser acknowledges
that the removal of the restrictive legend from certificates representing Shares and Conversion Shares as set forth in this Section is
predicated upon the Company’s reliance upon this understanding and that any counsel to the Company will be entitled to rely on this
acknowledgment in connection with the opinion(s) described in Section 4.1(a).

 

4.2 Integration. The
Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section
2 of the Securities Act) that would be integrated with the offer or sale of the Shares for purposes of the rules and regulations of any
Trading Market such that it would require shareholder approval prior to the closing of such other transaction unless shareholder approval
is obtained before the closing of such subsequent transaction.

 

4.3 Securities Laws Disclosure;
Publicity. The Company shall, during the Disclosure Window, (a) issue a press release disclosing the material terms of the transactions
contemplated hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto, with the Commission
within the time required by the Exchange Act. From and after the issuance of such press release, the Company represents to the Purchaser
that it shall have publicly disclosed all material, non-public information delivered to any of the Purchaser by the Company or any of
its Subsidiaries, or any of their respective officers, directors, employees or agents in connection with the transactions contemplated
by the Transaction Documents. In addition, effective upon the issuance of such press release, the Company acknowledges and agrees that
any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries
or any of their respective officers, directors, agents, employees or Affiliates on the one hand, and any of the Purchaser or any of their
Affiliates on the other hand, shall terminate. The Company and Purchaser shall consult with each other in issuing any other press releases
with respect to the transactions contemplated hereby, and neither the Company nor Purchaser shall issue any such press release nor otherwise
make any such public statement without the prior consent of the Company, with respect to any press release of Purchaser, or without the
prior consent of Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed,
except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with prior notice
of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of Purchaser,
or include the name of Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior written
consent of Purchaser, except (a) as required by federal securities law in connection with the filing of final Transaction Documents with
the Commission and (b) to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall
provide the Purchaser with prior notice of such disclosure permitted under this clause (b).

 

4.4 Shareholder Rights
Plan. No claim will be made or enforced by the Company or, with the consent of the Company, by any other Person, that Purchaser is
an “Acquiring Person” under any control share acquisition, business combination, poison pill (including any distribution
under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that Purchaser
could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Shares under the Transaction Documents
or under any other agreement between the Company and the Purchaser.

 

    	 	21	 

     

    

 

4.5 Non-Public Information.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, which shall be
disclosed pursuant to Section 4.3, the Company covenants and agrees that neither it, nor any other Person acting on its behalf
will provide Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes constitutes,
material non-public information, unless prior thereto Purchaser shall have consented to the receipt of such information and agreed with
the Company to keep such information confidential. The Company understands and confirms that Purchaser shall be relying on the foregoing
covenant in effecting transactions in securities of the Company. To the extent that the Company delivers any material, non-public information
to a Purchaser without Purchaser’s consent, the Company hereby covenants and agrees that Purchaser shall not have any duty of confidentiality
to the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates, or a duty to
the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees or Affiliates not to trade on the
basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable law. To the extent that
any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information regarding the Company
or any Subsidiaries, the Company shall simultaneously file such material non-public information with the Commission pursuant to a Current
Report on Form 8-K. The Company understands and confirms that the Purchaser shall be relying on the foregoing covenant in effecting transactions
in securities of the Company.

 

4.6 Use of Proceeds.
The Company shall use the net proceeds from the sale of the Shares hereunder as set forth on Schedule 4.6 attached hereto following
the Closing.

 

4.7 Indemnification
of Purchaser. Subject to the provisions of this Section 4.7, the Company will indemnify and hold Purchaser and its
directors, officers, managers, advisors, brokers, shareholders, members, partners, employees and agents (and any other Persons with
a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person
who controls Purchaser (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the
directors, officers, managers, advisers, brokers, shareholders, agents, members, partners or employees (and any other Persons with a
functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such
controlling persons (each, a “Purchaser Party”) harmless from any and all losses, liabilities, obligations,
claims, contingencies, damages, costs and reasonable expenses, including all judgments, amounts paid in settlements, court costs and
reasonable attorneys’ fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of or
relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement
or in the other Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity, or any of them or
their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any
of the transactions contemplated by the Transaction Documents (unless such action is based upon a material breach of such Purchaser
Party’s representations, warranties or covenants under the Transaction Documents or any agreements or understandings such
Purchaser Party may have with any such stockholder or any violations by such Purchaser Party of state or federal securities laws or
any conduct by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful
misconduct). If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this
Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right to assume the
defense thereof with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the
right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such
counsel shall be at the expense of such Purchaser Party except to the extent that (x) the employment thereof has been specifically
authorized by the Company in writing, (y) the Company has failed after a reasonable period of time to assume such defense and to
employ counsel or (z) in such action there is, in the reasonable opinion of counsel, a material conflict on any material issue
between the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible for the
reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under
this Agreement (1) for any settlement or compromise of, or consent to the entry of judgement in, any Action or Proceeding by a
Purchaser Party effected without the Company’s prior written consent, which shall not be unreasonably withheld or delayed; or
(2) to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party’s
breach of any of the representations, warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the
other Transaction Documents. The indemnification required by this Section 4.7 shall be made by periodic payments of the
amount thereof during the course of the investigation or defense, as and when bills are received or are incurred. The indemnity
agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company
or others and any liabilities the Company may be subject to pursuant to law.

 

    	 	22	 

     

    

 

4.8 Listing of Common Stock.
The Company hereby agrees to use best efforts to maintain the listing of the Common Stock on the Trading Market on which it is currently
listed. The Company will comply in all respects with the Company’s reporting, filing and other obligations under the bylaws or rules
of the Trading Market. For so long as the Company maintains a listing or quotation of the Common Stock on a Trading Market, the Company
agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another established
clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established
clearing corporation in connection with such electronic transfer.

 

4.9 Restrictions on Sale,
Conversion and Voting of Preferred Stock.

 

(a) From the date hereof up
to and including the Authorized Common Stock Increase Date, Purchaser, covenants that Purchaser will not convert any Shares and Purchaser
will not transfer, offer, sell, contract to sell, hypothecate, pledge or otherwise dispose of (or enter into any transaction which is
designed to, or might reasonably be expected to, result in the disposition (whether by actual disposition or effective economic disposition
due to cash settlement or otherwise)) any Shares or shares of Common Stock issuable upon conversion of the Shares.

 

(b) Purchaser covenants to (i)
vote, and, if applicable, shall cause its Affiliates to vote, all shares of Series C Stock owned by Purchaser or its Affiliates, as applicable,
in favor of any resolution presented to the shareholders of the Company for the purpose of obtaining the Stockholder Approvals, and (ii)
promptly upon request by the Company, grant the Company (or its designee) an irrevocable proxy, in form and substance reasonably satisfactory
to Purchaser, to vote all shares of Series C Stock in accordance with clause (i) above, in each case, in accordance with the provisions
of the Series C Certificate of Designations.

 

(c) Purchaser covenants to
(i) vote, and, if applicable, shall cause its Affiliates to vote, all shares of Series D Stock owned by Purchaser or its Affiliates,
as applicable, on any resolution presented to the stockholders of the Company for purposes of obtaining the Stockholder Approvals
and agrees that such shares of Series D Stock shall automatically and without further action of the Purchaser be voted in a manner
that “mirrors” the proportions on which the shares of Common Stock (excluding any shares of Common Stock that are not
voted) and Series C Stock are voted on the Authorized Common Stock Increase and Name Change, and any adjournment of any meeting of
stockholders called for the purpose of voting on the Authorized Common Stock Increase as set forth in the Series D Certificate of
Designation; and (ii) promptly upon request by the Company, grant the Company (or its designee) an irrevocable proxy to vote all
shares of Series D Stock in accordance with clause (i) above. For the avoidance of doubt, and for illustrative purposes only, if 30%
of the aggregate votes cast by Common Stock and Series C Stock voting in connection with the Authorized Common Stock Increase and
Name Change are voted against such resolutions and 70% of the aggregate votes cast by Common Stock and Series C Stock voting in
connection with the Authorized Common Stock Increase and Name Change are voted in favor thereof, then 30% of the votes cast by the
shares of Series D Stock voting in connection with the Authorized Common Stock Increase and Name Change shall vote against the
approval of the Authorized Common Stock Increase and Name Change and 70% of such votes shall be cast in favor of such Authorized
Common Stock Increase and Name Change.

 

    	 	23	 

     

    

 

4.10 Equal Treatment of
Purchaser. No consideration (including any modification of any Transaction Document) shall be offered or paid to any Person to amend
or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is also offered to
all of the parties to such Transaction Documents. For clarification purposes, this provision constitutes a separate right granted to Purchaser
by the Company and negotiated separately by Purchaser, and is intended for the Company to treat the Purchaser as a class and shall not
in any way be construed as the Purchaser acting in concert or as a group with respect to the purchase, disposition or voting of Shares
or otherwise.

 

4.11 Certain Transactions
and Confidentiality. Purchaser covenants that neither it nor any Affiliate acting on its behalf or pursuant to any understanding with
it will execute any purchases or sales, including Short Sales of any of the Company’s securities during the period commencing with
the execution of this Agreement and ending at such time that the transactions contemplated by this Agreement are first publicly announced
pursuant to the initial press release as described in Section 4.3. Purchaser covenants that until such time as the transactions
contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described in Section
4.3, Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information included in the
Disclosure Schedules. Notwithstanding the foregoing, and notwithstanding anything contained in this Agreement to the contrary, the Company
expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty or covenant hereby that it will not engage
in effecting transactions in any securities of the Company after the time that the transactions contemplated by this Agreement are first
publicly announced pursuant to the initial press release as described in Section 4.3, (ii) no Purchaser shall be restricted or
prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws from and after
the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described
in Section 4.3 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the Company
to the Company or its Subsidiaries after the issuance of the initial press release as described in Section 4.3. Notwithstanding
the foregoing in the event Purchaser is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions
of Purchaser’s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers
managing other portions of Purchaser’s assets, the covenant set forth above shall only apply with respect to the portion of assets
managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement.

 

4.12 Form D. The Company
agrees to timely file a Form D with respect to the Shares as required under Regulation D and to provide a copy thereof, promptly upon
request of Purchaser.

 

4.13 Registration of
Common Stock Issuable upon Conversion of the Shares. The Company shall file a registration statement on Form S-3 (or, if Form
S-3 is not then available to the Company, other appropriate form) providing for the resale by the Purchaser of the Conversion Shares
no later than forty-five (45) days following the date of this Agreement (the “Filing Deadline”). The Company
shall use reasonable best efforts to cause such Form S-3 (or other appropriate form) to be declared effective as soon as possible
after filing, but in no event later to sixty (60) days following the Filing Deadline (such date of effectiveness, the
 “Effectiveness Date”). Once effective, the Company shall use reasonable best efforts to keep such Form S-3 (or
other appropriate form) continuously effective and shall cause it to be supplemented and amended to the extent necessary to ensure
such Form S-3 (or other appropriate form) is available. The Company shall notify the Purchaser in writing of the effectiveness of
such Form S-3 (or other appropriate form) as soon as practicable, but in any event within one (1) Business Day after it becomes
effective. 

 

    	 	24	 

     

    

 

4.14 Stockholder Approvals.
The Company shall use its reasonable best efforts to obtain the Stockholder Approvals on or before September 30, 2022. 

 

ARTICLE V.

MISCELLANEOUS

 

5.1 Termination. This
Agreement may be terminated by Purchaser, by written notice to the Company, if the Closing has not been consummated on or before the fifth
(5th) Trading Day following the date hereof.

 

5.2 Fees and Expenses.
Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers,
counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation,
execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without limitation, any
fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice delivered by a Purchaser),
stamp taxes and other taxes and duties levied in connection with the delivery of any Shares to the Purchaser.

 

5.3 Entire Agreement.
The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of the parties with respect
to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such
matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.

 

5.4 Notices. Any and
all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed
given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered via facsimile at the
facsimile number or email attachment at the email address as set forth below at or prior to 5:30 p.m. (New York City time) on a Trading
Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered via facsimile at the facsimile
number or email attachment at the email address as set forth below on a day that is not a Trading Day or later than 5:30 p.m. (New York
City time) on any Trading Day, (c) the second (2nd) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight
courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and
communications shall be as set forth below:

 

If to the Company:

 

Synthetic Biologics, Inc.

19605 Medical Center Drive,
Suite 270

Rockville, Maryland 20850

Attn:    Steven
A. Shallcross

             Chief
Executive Officer

Email: ***

 

    	 	25	 

     

    

 

with a copy (which shall not
constitute notice) to:

 

Blank Rome LLP

1271 Avenue of the Americas

New York, New York 10020

Attn: Leslie Marlow

Email: ***

If to the Purchaser:

 

to the address set forth on
the signature page hereto.

 

5.5 Amendments; Waivers.
No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of
an amendment prior to Closing by the Purchaser, and after Closing, by the Company and the Purchaser or, in the case of a waiver, by the
party against whom enforcement of any such waived provision is sought. No waiver of any default with respect to any provision, condition
or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver
of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder
in any manner impair the exercise of any such right. Any amendment effected in accordance with this Section 5.5 shall be binding
upon Purchaser and each holder of Shares and the Company.

 

5.6 Headings. The headings
herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions
hereof.

 

5.7 Successors and Assigns.
This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Company may
not assign this Agreement or any rights or obligations hereunder without the prior written consent of Purchaser (other than by merger).
Purchaser may assign any or all of its rights under this Agreement to any Person to whom Purchaser assigns or transfers any Shares, provided
that such transferee agrees in writing to be bound, with respect to the transferred Shares, by the provisions of the Transaction Documents
that apply to the Purchaser.

 

5.8 No Third-Party Beneficiaries.
The Financial Advisor shall be the third-party beneficiary of the representations and warranties of the Company in Section 3.1
and the representations and warranties of the Purchaser in Section 3.2. This Agreement is intended for the benefit of the parties
hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by,
any other Person, except as otherwise set forth in Section 4.7 and this Section 5.8.

 

5.9 Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be
governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all Actions or Proceedings concerning the interpretations,
enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought
against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents)
shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably
submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the
adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein
(including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to
assert in any action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such
action or proceeding is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives personal
service of process and consents to process being served in any such action or proceeding by mailing a copy thereof via registered or
certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this
Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained
herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall
commence an action or proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the
Company under Section 4.7, the prevailing party in such action or proceeding shall be reimbursed by the non-prevailing party
for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution
of such action or proceeding.

 

    	 	26	 

     

    

 

5.10 Survival. The
covenants, representations and warranties contained herein shall survive the Closing and the delivery of the Shares for a period of five
(5) years from the Closing.

 

5.11 Execution. This
Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that
the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery
of a “.pdf’ format data file, such signature shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original
thereof.

 

5.12 Severability.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.

 

5.13 Rescission and Withdrawal
Right. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of the other Transaction
Documents, whenever Purchaser exercises a right, election, demand or option under a Transaction Document and the Company does not timely
perform its related obligations within the periods therein provided, then Purchaser may rescind or withdraw, in its sole discretion from
time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to its
future actions and rights.

 

 

5.14 Replacement of Shares.
If any certificate or instrument evidencing any Shares is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be
issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor,
a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction.
The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including
customary indemnity) associated with the issuance of such replacement Shares.

 

    	 	27	 

     

    

 

5.15 Remedies. In addition
to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchaser and the
Company will be entitled to seek specific performance under the Transaction Documents. The parties agree that monetary damages may not
be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby
agree to waive and not to assert in any action for specific performance of any such obligation the defense that a remedy at law would
be adequate.

 

5.16 Payment Set Aside.
To the extent that the Company makes a payment or payments to Purchaser pursuant to any Transaction Document or a Purchaser enforces or
exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are
subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded,
repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including, without limitation, any
bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation
or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not
been made or such enforcement or setoff had not occurred.

 

5.17 Independent Nature
of Purchaser’s Obligations and Rights. The Purchaser have been represented by its own separate legal counsel in its review and
negotiation of the Transaction Documents. For reasons of administrative convenience only, the Purchaser and its counsel have chosen to
communicate with the Company through the legal counsel of the Financial Advisor. The legal counsel of the Financial Advisor does not represent
the Purchaser and only represents the Financial Advisor.

 

5.18 Saturdays, Sundays,
Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein
shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.

 

5.19 Construction.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall
not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to
share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.

 

5.20 WAIVER OF JURY
TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES
EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY
AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. 

 

(Signature Pages Follow) 

 

    	 	28	 

     

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of
the date first indicated above.

 	 	SYNTHETIC BIOLOGICS, INC.
	 
	 	By: 	/s/ Steven A. Shallcross
	 	Name: Steven A. Shallcross
	 	Title: Chief Executive Officer

 

[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK

SIGNATURE
PAGE FOR PURCHASER FOLLOWS]

 

    	 	29	 

     

    

 

[PURCHASER SIGNATURE PAGE TO SECURITIES PURCHASE
AGREEMENT]

 

IN WITNESS WHEREOF,
the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the
date first indicated above.

 

Name of Purchaser: MSD Credit Opportunity Master
Fund, L.P.

 

Signature of Authorized Signatory of
Purchaser: /s/ Marcello Liguori                                                                             

 

Name of Authorized Signatory: Marcello Liguori

 

Title of Authorized Signatory: Managing Director

 

Email Address of Authorized Signatory: mliguori@msdpartners.com

  

Address for Notice to Purchaser: 1 Vanderbilt Avenue,
26th Floor, New York, NY 10017

 

DWAC for Shares:                                                                                                                                                                               

 

Subscription Amount for Series C Stock: $2,200,000

 

Shares of Series C Stock: 275,000

 

Subscription Amount for Series D Stock: $800,000

 

Shares of Series D Stock: 100,000

 

EIN Number: ***

 

    	 	30

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]